Changing the Subject (Part 3): The “All-Cancer Trial”

 
• By Michael McCaughan

Rather than try to “win” the drug pricing debate, the biopharma sector may be better served by coming up with new ideas to change the subject. We outlined our case for taking this approach – and the model for ideas that serve that goal – here. Now we offer our second proposal: a nationwide clinical trial open to every patient with a cancer diagnosis.

Cancer has an outsized prominence in public policy related to health care, and cancer drug costs are not surprisingly an outsized issue in the drug pricing debate.

Thankfully, the prices are accompanied by an unprecedented wave of highly effective new therapies, some targeted very narrowly to specific mutations in some subset of tumors, some seemingly broadly

More from Market Access

More from Pink Sheet